Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Kopran
Small Cap•842 Employees•IPO 1992
Current Price
₹113.01
-3.24 (-2.79%)Updated
Today's Range
111.6
₹113.01
117.08
52 Week Range
52W Low₹116.00
52W High₹214.00
₹113.01
Downside-2.58%
Upside89.36%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹640.51 Cr
Market Cap
Total market value of companyP/E Ratio
38.72
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
1.68
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹3.41
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-0.05%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
9.75%
ROCE
Return on Capital Employed. >15% is goodNet Margin
2.67%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
10.49%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
11.86%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-3.03%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-32.90%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.29
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹107.35
Book Value
Net asset value per shareDividend Yield
2.26%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
44.40%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Kopran Ltd exhibits a relatively low debt-to-equity ratio of 0.29, suggesting a manageable debt burden and a strong financial foundation for future growth and investment opportunities. This indicates a healthy balance sheet.
- •Despite recent quarterly profit variability, Kopran's promoter holding remains consistently high at approximately 44%, demonstrating significant confidence in the company's long-term prospects and potential for future value appreciation.
Weaknesses
5 points- •Kopran Ltd's quarterly profit has shown significant volatility, with a substantial -32.90% decrease in the most recent quarter. This needs further investigation to understand the underlying causes and potential future impact.
- •The recent stock price has experienced considerable fluctuation, falling from a 52-week high of ₹327 to a low of ₹154. This volatility presents a risk for investors seeking stability in their portfolios.
Opportunities
3 points- •The pharmaceutical industry, where Kopran operates, is experiencing robust growth driven by increasing global healthcare expenditure and an aging population, presenting significant market expansion opportunities.
- •Kopran's relatively low debt-to-equity ratio of 0.29 provides financial flexibility for strategic investments, potential acquisitions, or R&D to diversify its product portfolio and capture new market segments.
Threats
4 points- •Kopran faces intense competition from larger, more established pharmaceutical players with significantly higher market capitalization and R&D budgets, potentially limiting its market share and pricing power.
- •The pharmaceutical sector is highly susceptible to stringent regulatory changes and evolving compliance standards, which could increase operational costs and impact product approvals for Kopran.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Mridula Somani | 18 Dec 2024 | 20 Dec 2024 | 26.37 L | 17.65 L | - | BUY |
Mridula Somani | 18 Dec 2024 | 08 Jan 2025 | 25.53 L | 17.65 L | - | BUY |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹127.15 | +₹14.14 | +12.52% |
| R3 | ₹121.67 | +₹8.66 | +7.67% |
| R2 | ₹119.38 | +₹6.37 | +5.63% |
| R1 | ₹116.19 | +₹3.18 | +2.82% |
| PIVOT | ₹113.90 | 0.89 | 0.78% |
| CURRENT | ₹113.01 | - | - |
| S1 | ₹99.75 | -₹13.26 | -11.73% |
| S2 | ₹105.23 | -₹7.78 | -6.88% |
| S3 | ₹108.42 | -₹4.59 | -4.06% |
| S4 | ₹110.71 | -₹2.30 | -2.03% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+83.5% vs avg
3.42L
(13 Mar 2026)Delivery %+6.3% vs avg
51.7%
(13 Mar 2026)Avg Volume (20D)20-day average
1.86L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
45.4%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Wanbury Ltd
1197.00 %
Highest Dividend Yield
Anuh Pharma Ltd
1.85 %
Peer Comparison
| Company Name |
|---|
 |
 |
 Anuh Pharma Ltd |
 Ind-Swift Laboratories Ltd |
 Kilitch Drugs (India) Ltd |
 Medicamen Biotech Ltd |
 Sakar Healthcare Ltd |
 Sigachi Industries Ltd |
 Sun Pharmaceutical Industries Ltd |
 Themis Medicare Ltd |
 Wanbury Ltd |
About
Kopran Ltd
Kopran Limited is an integrated pharmaceutical company with a long history, established in 1958 and headquartered in Mumbai, India. Its core business revolves around the manufacturing and marketing of both Active Pharmaceutical Ingredients (APIs) and finished dosage forms of pharmaceuticals. This encompasses a broad range of products distributed both domestically within India and internationally.
The company's product portfolio is extensive and diverse, covering numerous therapeutic categories. Their finished dosage forms include a variety of common pharmaceutical presentations such as tablets, capsules, syrups, dry powders, suspensions, and injectables. These forms are utilized to deliver medications across a wide spectrum of therapeutic areas.
Kopran offers both branded and generic formulations of drugs. The therapeutic areas covered by their products are substantial, including but not limited to: macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, anti-acne medications, anti-infectives, anti-thrombotics, antidiabetics, pain management medications, neuromodulators, gastroenterology drugs, and cardiovascular medications. Furthermore, their offerings extend to drugs for erectile dysfunction, antiallergics, respiratory medications, oncology drugs, central nervous system medications, antiprotozoals, anthelmintics, antipeptic ulcer and gut medications, and various other therapeutic categories.
In summary, Kopran Limited operates as a fully integrated pharmaceutical company, encompassing API production and the manufacturing and marketing of a wide range of finished dosage forms across numerous therapeutic areas. Their long history and diverse product portfolio establish them as a significant player in the Indian and international pharmaceutical markets.
COMPANY FACTS - KOPRAN
Registered Address
Parijat House, 1076, Dr. E. Moses Road, Worli
Mumbai
MAHARASHTRA
IN
Tel: 912243661111
Website:https://www.kopran.com/
Investor Relations:http://www.kopran.com/investors/financials/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 842
IPO Date: 17/11/1992
MANAGEMENT - KOPRAN
Shri. Susheel Somani
Non-Executive Chairman of the Board
Shri. Surendra Somani
Executive Vice Chairman of the Board
Mr. Basant Soni
Chief Financial Officer
Mr. Sunil Sodhani
Compliance Officer, Company Secretary
Mr. Adarsh Somani
Additional Non-Executive Director
Mr. Varun Somani
Additional Non-Executive Director
Mr. Narayan Atal
Non-Executive Independent Director
Dr. Sunita Banerji
Non-Executive Independent Director
Mrs. Mamta Biyani
Non-Executive Independent Director
Dr. Siddhan Subramanian
Non-Executive Independent Director
Ms. Chandni Shah
Investor Relations
Investor Questions Answered
Kopran Ltd (KOPRAN) Stock FAQs
Get answers to the most common questions about Kopran Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Kopran Ltd (KOPRAN) is ₹113.01. Today, the stock has declined by ₹3.24 (2.79%), trading in a range of ₹111.6 to ₹117.08. The stock opened at ₹115.67 with a trading volume of 1,29,275 shares.
Kopran Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹640.51 crores, P/E ratio of 38.72, ROE of -0.05%, and ROCE of 9.75%. The dividend yield stands at 2.26%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Kopran Ltd (KOPRAN) is ₹214, while the 52-week low is ₹116. Currently trading at ₹113.01, the stock is -3.1% away from its 52-week low and 47.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Kopran Ltd stock at ₹113.01 depends on multiple factors. The stock is currently trading with a P/E ratio of 38.72 and P/B ratio of N/A. Today's performance shows a loss of 2.79%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Kopran Ltd offers a dividend yield of 2.26%, which means for every ₹100 invested at the current price of ₹113.01, you can expect to receive approximately ₹2.26 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Kopran Ltd's key financial metrics include: P/E Ratio: 38.72, P/B Ratio: N/A, ROE: -0.05%, ROCE: 9.75%, Dividend Yield: 2.26%, EPS: ₹3.41, Book Value: ₹107.35, Debt-to-Equity: 0.29, and Current Ratio: N/A. The company's market cap stands at ₹640.51 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Kopran Ltd stock opened at ₹115.67 and is currently trading at ₹113.01, showing a decline of ₹3.24 (2.79%). The intraday high is ₹117.08 and low is ₹111.6. The trading volume stands at 1,29,275 shares, indicating moderate market participation today.
Kopran Ltd has a Price-to-Earnings (P/E) ratio of 38.72, which means investors are willing to pay ₹38.72 for every ₹1 of earnings. With an EPS of ₹3.41, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Kopran Ltd has a market capitalization of ₹640.51 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹113.01) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Kopran Ltd has a book value of ₹107.35 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹113.01, which is 5.3% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Kopran Ltd has a Return on Equity (ROE) of -0.05% and Return on Capital Employed (ROCE) of 9.75%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Kopran Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Kopran Ltd has a debt-to-equity ratio of 0.29, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Kopran Ltd has an Earnings Per Share (EPS) of ₹3.41, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹113.01 and P/E ratio of 38.72, investors are paying 38.72 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Kopran Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Kopran Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Kopran Ltd stock, consider: 1) Fundamental Analysis - Review P/E (38.72), ROE (-0.05%), debt-to-equity (0.29), and growth rates. 2) Technical Analysis - Check 52-week range (₹116.00 - ₹214.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹113.01) with book value (₹107.35) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Kopran Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹113.01 is 1030x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Kopran Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹116.00 - ₹214.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.29 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,29,275 shares. 5) Valuation Risk - P/E of 38.72 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Kopran Ltd operates in the industry with key metrics: P/E ratio of 38.72, ROE of -0.05%, market cap of ₹640.51 crores, and dividend yield of 2.26%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.29), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Kopran Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹113.01, with a 52-week range of ₹116.00 to ₹214.00. Based on fundamentals like P/E (38.72), ROE (-0.05%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Kopran Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹113.01. 2) Fundamental Deterioration - Declining ROE (currently -0.05%), increasing debt (D/E: 0.29), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Kopran Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 2.26%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu